Vaccine and Infectious Disease Organization (VIDO)
The University of Saskatchewan’s Vaccine and Infectious Disease Organization (VIDO) works at the forefront of emerging life sciences technologies and aims to anticipate emerging infectious disease. Research opportunities are available in groundbreaking areas of human and animal health (see www.vido.org , Research).
VIDO is currently leading the development of the $140 million International Vaccine Centre (InterVac), an ambitious new Biosafety Level 3 facility at the University of Saskatchewan to be completed by 2010. This research and development facility will enhance Canada’s capacity to develop vaccines for both humans and animals. One of the largest vaccine research labs in North America, InterVac’s capabilities will be sought after internationally.
Leading scientists find VIDO an exceptional place to work because of its team culture. Members of nearly all research teams participate in meetings with partners and collaborators including multinational pharmaceutical companies. Through these collaborations, VIDO offers a unique opportunity to gain experience in both industry and academia.
VIDO is driven by defined research goals aimed at benefiting health and quality of life for both humans and animals. The protection of intellectual property is emphasized, ensuring research will lead to products that can be licensed or patented.
Graduate students and trainees appreciate the opportunity to conduct their research in areas that will provide practical benefits to human and animal health. They find the team culture of VIDO scientists—molecular biologists, virologists, immunologists, bacteriologists, biochemists and veterinarians—makes for a stimulating learning environment.
An expansion opened in 2003 offers more than $4 million of state-of-the-art equipment, ensuring students will graduate adept at using new technologies, making them competitive candidates for future positions. Former VIDO trainees and staff are now in senior positions in academia, industry and government around the world.
Run by a compact and efficient administrative team, VIDO ensures open channels between researchers and senior administrators.
VIDO’s team culture also enables it to seize emerging research opportunities: it partnered in the development of a recently-approved vaccine to protect food and water from E. coli O157:H7. It has already made progress towards a vaccine against avian influenza, and helped generate three SARS vaccine candidates within 18 months of the disease’s emergence.
VIDO has been successful in attracting scientists and trainees from around the world and currently has staff from more than 20 countries. Social functions incorporate VIDO’s diverse cultures. Many of VIDO’s staff came to VIDO for academic training and secured permanent positions, making Saskatoon their home.
More about VIDO
- Fast Facts
- VIDO News Features